---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-168644"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T23:03:46.805190+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences Q2 2025 net loss $50.5M; cash $208.5M; key trial data on track

## Summary
- Cash $208.5M as of June 30, 2025, down from $302.1M at Dec 31, 2024; runway into 2027.
- Revenue $8.7M in Q2 2025 vs $19.7M YoY; net loss $50.5M vs $32.9M YoY.
- WVE-006 AATD: multidose complete in 200mg cohort; 200mg data in 3Q 2025, 400mg data fall 2025.
- WVE-007 obesity: expanded Cohort 2 (240mg) to 32; data from Cohorts 1 and 2 expected 4Q 2025.
- Appointed Christopher Wright, MD, PhD, as Chief Medical Officer in May 2025.

## SEC filing metadata
- accession: 0001193125-25-168644
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312525168644/0001193125-25-168644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312525168644/d157278d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-168644
- JSON: https://secwatch.observer/filing/0001193125-25-168644.json
- Plain text: https://secwatch.observer/filing/0001193125-25-168644.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.